New shot targets genetic form of fatty liver disease

NCT ID NCT05809934

Disease control Sponsor: AstraZeneca Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tested a monthly injection called AZD2693 in 220 adults with non-alcoholic steatohepatitis (NASH) and liver scarring, who carry a specific genetic risk factor. The goal was to see if the drug could reverse liver inflammation and scarring without making it worse. The trial is now complete, and results will show whether AZD2693 is safe and effective for this condition.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance: AZD2693
What this could lead to: If successful, AZD2693 could become a treatment to reverse liver inflammation and scarring in people with a specific genetic risk for NASH.
What could go wrong: This is a mid-stage trial with only 220 participants, so results may not confirm benefit. The drug is still experimental and may not improve liver health or could cause side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 2

Tests whether the treatment actually works, and watches for side effects, in a larger group.

Participants

220 people

The number who actually took part.

Started

Mar 2023

Finished

Sep 2025

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 75 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Key Inclusion Criteria : Participants are eligible to be included in the study only if all the following criteria apply: Age 1. Participant must be 18 to 75 years of age (inclusive) at the time of signing the informed consent. Type of Participant and Disease Characteristics 2. Participants who are carriers for the PNPLA3 rs738409 148M risk allele. 3. Participants with histological evidence of NASH based on central pathologist evaluation of a liver biopsy obtained up to 6 months before randomisation, or during screening, fulfilling both criteria: 1. Definitive NASH with NAS ≥ 4 with ≥ 1 in each component (ie, steatosis, lobular inflammation, and ballooning).  1. Presence of fibrosis stage F2 or F3 according to the NASH CRN fibrosis staging system based on central pathologist evaluation. Key Exclusion Criteria : Participants are excluded from the study if any of the following criteria apply: Medical Conditions 1. Liver disease of other aetiologies (eg, alcoholic steatohepatitis; drug-induced, viral or autoimmune hepatitis; primary biliary cirrhosis; primary sclerosing cholangitis; hemochromatosis; alpha-1 antitrypsin deficiency; Wilson's disease) 2. History of cirrhosis and/or hepatic decompensation, including ascites, hepatic encephalopathy, or variceal bleeding. 3. Historical persistent or pre-existing renal disease marked by eGFR \< 40 mL/min/1.73 m2 (as defined by Kidney Disease Improving Global Outcomes guidelines). 4. Confirmed platelet count outside the normal range at the screening visit. 5. Any of the following confirmed at the screening visit: 1. ALT \> 5.0 × ULN 2. TBL \> 1.5 mg/dL (TBL \> 1.5 mg/dL is allowed if conjugated bilirubin is \< 1.5 × ULN) 3. INR \> 1.3 4. ALP \> 1.5 × ULN (unless the ALP elevation is not from hepatic origin as determined by a bone-specific ALP)

Get updates

Get notified about this study

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

cirrhosis of liver metabolic dysfunction-associated steatohepatitis metabolic dysfunction-associated steatotic liver disease

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Nonalcoholic steatohepatitis

Contacts and locations

Locations

Research Site

Chandler, Arizona, 85224, United States
Research Site

Peoria, Arizona, 85381, United States
Research Site

Surprise, Arizona, 85378, United States
Research Site

Tucson, Arizona, 85712, United States
Research Site

Tucson, Arizona, 85715, United States
Research Site

Gardena, California, 90247, United States
Research Site

La Mesa, California, 91942, United States
Research Site

Lancaster, California, 93534, United States
Research Site

Los Angeles, California, 90057, United States
Research Site

Montclair, California, 91763, United States
Research Site

Orange, California, 92868, United States
Research Site

Rialto, California, 92377, United States
Research Site

Santa Ana, California, 92704, United States
Research Site

Boca Raton, Florida, 33434, United States
Research Site

Hialeah, Florida, 33016, United States
Research Site

Jacksonville, Florida, 32216, United States
Research Site

Port Orange, Florida, 32127, United States
Research Site

Winter Park, Florida, 32792, United States
Research Site

Marietta, Georgia, 30060, United States
Research Site

Topeka, Kansas, 66606, United States
Research Site

Detroit, Michigan, 48202, United States
Research Site

Las Vegas, Nevada, 89101, United States
Research Site

Westlake, Ohio, 44145, United States
Research Site

Chickasha, Oklahoma, 73018, United States
Research Site

Hershey, Pennsylvania, 17033, United States
Research Site

Summerville, South Carolina, 29485, United States
Research Site

Cordova, Tennessee, 38018, United States
Research Site

Austin, Texas, 78757, United States
Research Site

Brownsville, Texas, 78520, United States
Research Site

Denison, Texas, 75020, United States
Research Site

Edinburg, Texas, 78539, United States
Research Site

Houston, Texas, 77030, United States
Research Site

Red Oak, Texas, 75154, United States
Research Site

San Antonio, Texas, 78229, United States
Research Site

Sugar Land, Texas, 77479, United States
Research Site

Richmond, Virginia, 23249, United States
Research Site

Seattle, Washington, 98105, United States
Research Site

CABA, C1119ACN, Argentina
Research Site

CABA, C1426, Argentina
Research Site

Ciudad de Buenos Aires, 1280, Argentina
Research Site

Córdoba, X5000EPU, Argentina
Research Site

La Plata, 1900, Argentina
Research Site

Mar del Plata, B7600GNY, Argentina
Research Site

San Juan Bautista, 1888, Argentina
Research Site

Botucatu, 18618-687, Brazil
Research Site

Porto Alegre, 90035-000, Brazil
Research Site

Porto Alegre, 90035-903, Brazil
Research Site

Salvador, 40110-160, Brazil
Research Site

São José do Rio Preto, 15090-000, Brazil
Research Site

São Paulo, 05403-000, Brazil
Research Site

Santiago, 7620157, Chile
Research Site

Santiago, 8380456, Chile
Research Site

Santiago, Chile
Research Site

Valdivia, 5110683, Chile
Research Site

Baotou, 014010, China
Research Site

Beijing, 100057, China
Research Site

Beijing, 100069, China
Research Site

Chengdu, 610072, China
Research Site

Fuzhou, 350005, China
Research Site

Guangzhou, 510515, China
Research Site

Hangzhou, 310003, China
Research Site

Liaocheng, 252000, China
Research Site

Nanchang, 330000, China
Research Site

Qingdao, 266011, China
Research Site

Shanghai, 200025, China
Research Site

Shanghai, 200080, China
Research Site

Shanghai, 200092, China
Research Site

Shenyang, 110004, China
Research Site

Taiyuan, 030001, China
Research Site

Wenzhou, 325000, China
Research Site

Xi'an, 710061, China
Research Site

Xuzhou, 221000, China
Research Site

Zhenjiang, 212021, China
Research Site

Cartagena, 130013, Colombia
Research Site

Konstanz, 78464, Germany
Research Site

Magdeburg, Germany
Research Site

Mainz, 55131, Germany
Research Site

Münster, 48149, Germany
Research Site

Hong Kong, 999077, Hong Kong
Research Site

Shatin, Hong Kong
Research Site

Hyderabad, 500072, India
Research Site

Jaipur, 302001, India
Research Site

Jaipur, 302018, India
Research Site

Punjab, 160062, India
Research Site

Surat, 395009, India
Research Site

Milan, 20122, Italy
Research Site

Palermo, 90127, Italy
Research Site

Roma, 00128, Italy
Research Site

Rome, 00168, Italy
Research Site

Torino, 10126, Italy
Research Site

Bunkyō City, 113-8655, Japan
Research Site

Fukui-shi, 918-8503, Japan
Research Site

Fukuoka, 810-0065, Japan
Research Site

Gifu, 500-8513, Japan
Research Site

Kagoshima, 890-8520, Japan
Research Site

Kawasaki-shi, 215-0026, Japan
Research Site

Kobe, 650-0017, Japan
Research Site

Kumamoto, 860-8556, Japan
Research Site

Kure-shi, 737-0023, Japan
Research Site

Kurume-shi, 830-0011, Japan
Research Site

Kyoto, 602-8566, Japan
Research Site

Minatoku, 105-8470, Japan
Research Site

Nagoya, 460-0001, Japan
Research Site

Okayama, 700-8505, Japan
Research Site

Omura-shi, 856-8562, Japan
Research Site

Osaka, 545-8586, Japan
Research Site

Ōita, 870-0837, Japan
Research Site

Saga, 849-8501, Japan
Research Site

Shinjuku-ku, 160-0023, Japan
Research Site

Shinjuku-ku, 160-8582, Japan
Research Site

Shinjuku-ku, 162-8655, Japan
Research Site

Takasaki-shi, 370-0829, Japan
Research Site

Tsu, 514-8507, Japan
Research Site

Yokohama, 236-0004, Japan
Research Site

Yokohama, 245-8575, Japan
Research Site

Kota Kinabalu, 88586, Malaysia
Research Site

Kuala Lumpur, 56000, Malaysia
Research Site

Kuala Lumpur, 59100, Malaysia
Research Site

Pulau Pinang, 10450, Malaysia
Research Site

Seremban, 70300, Malaysia
Research Site

Acapulco, 39670, Mexico
Research Site

Guadalajara, 44340, Mexico
Research Site

Mexico City, 03330, Mexico
Research Site

Mexico City, 06700, Mexico
Research Site

Torreón, 27000, Mexico
Research Site

Veracruz, 91851, Mexico
Research Site

Xalapa, 91020, Mexico
Research Site

Chorrillos, Lima 9, Peru
Research Site

Lima, 15023, Peru
Research Site

Lima, 15036, Peru
Research Site

Lima, 15046, Peru
Research Site

Cebu, 6000, Philippines
Research Site

Puerto Princesa City, 5300, Philippines
Research Site

Roxas City, 5800, Philippines
Research Site

San Fernando City, 2000, Philippines
Research Site

Singapore, 119074, Singapore
Research Site

Singapore, 169608, Singapore
Research Site

Singapore, 308433, Singapore
Research Site

Junggu, 41944, South Korea
Research Site

Seoul, 03080, South Korea
Research Site

Seoul, 06351, South Korea
Research Site

A Coruña, 15006, Spain
Research Site

Almería, 04009, Spain
Research Site

Lleida, 25198, Spain
Research Site

Málaga, 29010, Spain
Research Site

Zaragoza, 50009, Spain
Research Site

Kaohsiung City, 80756, Taiwan
Research Site

Tainan, 70403, Taiwan
Research Site

Taipei, 10002, Taiwan
Research Site

Taipei, 112, Taiwan
Research Site

Taoyuan, 333, Taiwan
Research Site

Bangkok, 10330, Thailand
Research Site

Bangkok, 10400, Thailand
Research Site

Bangkok, 10700, Thailand
Research Site

Hat Yai, 90110, Thailand
Research Site

Khon Kaen, 40002, Thailand
Research Site

Adana, 01060, Turkey (Türkiye)
Research Site

Antalya, 07059, Turkey (Türkiye)
Research Site

Bursa, 16059, Turkey (Türkiye)
Research Site

Eskişehir, 26480, Turkey (Türkiye)
Research Site

Izmir, 35340, Turkey (Türkiye)
Research Site

Rize, 530020, Turkey (Türkiye)
Research Site

Ho Chi Minh City, 700000, Vietnam
Research Site

Ho Chi Minh City, 70000, Vietnam

More trials for these conditions

Other studies related to the condition(s) this trial covers.